Stock Scorecard
Stock Summary for Perspective Therapeutics Inc (CATX) - $2.56 as of 5/5/2025 2:42:23 PM EST
Total Score
9 out of 30
Safety Score
34 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CATX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CATX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CATX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CATX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for CATX (34 out of 100)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 3 |
Stock Price Trend (Max of 10) | 2 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 8 |
Analyst Buy Ratings (Max of 5) | 5 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 6 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for CATX
Company Overview |
|
---|---|
Ticker | CATX |
Company Name | Perspective Therapeutics Inc |
Country | USA |
Description | N/A |
Sector Name | LIFE SCIENCES |
Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
Most Recent Quarter | 12/31/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 2.56 |
Price 4 Years Ago | 3.88 |
Last Day Price Updated | 5/5/2025 2:42:23 PM EST |
Last Day Volume | 713,096 |
Average Daily Volume | 832,666 |
52-Week High | 19.10 |
52-Week Low | 1.60 |
Last Price to 52 Week Low | 60.00% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 50.99 |
Sector PE | 37.03 |
5-Year Average PE | -45.80 |
Free Cash Flow Ratio | 3.08 |
Industry Free Cash Flow Ratio | 41.76 |
Sector Free Cash Flow Ratio | 29.42 |
Current Ratio Most Recent Quarter | 12.68 |
Total Cash Per Share | 0.83 |
Book Value Per Share Most Recent Quarter | 4.11 |
Price to Book Ratio | 0.65 |
Industry Price to Book Ratio | 5.32 |
Sector Price to Book Ratio | 21.93 |
Price to Sales Ratio Twelve Trailing Months | 130.38 |
Industry Price to Sales Ratio Twelve Trailing Months | 4.31 |
Sector Price to Sales Ratio Twelve Trailing Months | 28.34 |
Analyst Buy Ratings | 10 |
Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
Total Shares Outstanding | 74,051,000 |
Market Capitalization | 189,570,560 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 2.42% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -70.46% |
Reported EPS 12 Trailing Months | -1.22 |
Reported EPS Past Year | -0.83 |
Reported EPS Prior Year | -0.18 |
Net Income Twelve Trailing Months | -79,279,000 |
Net Income Past Year | -79,279,000 |
Net Income Prior Year | -46,508,000 |
Quarterly Revenue Growth YOY | -30.60% |
5-Year Revenue Growth | -100.00% |
Operating Margin Twelve Trailing Months | -8,929.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 61,580,000 |
Total Cash Past Year | 61,580,000 |
Total Cash Prior Year | 9,238,000 |
Net Cash Position Most Recent Quarter | 59,955,000 |
Net Cash Position Past Year | 59,955,000 |
Long Term Debt Past Year | 1,625,000 |
Long Term Debt Prior Year | 1,676,000 |
Total Debt Most Recent Quarter | 1,625,000 |
Equity to Debt Ratio Past Year | 0.99 |
Equity to Debt Ratio Most Recent Quarter | 0.99 |
Total Stockholder Equity Past Year | 290,668,000 |
Total Stockholder Equity Prior Year | 75,179,000 |
Total Stockholder Equity Most Recent Quarter | 290,668,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -72,708,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.98 |
Free Cash Flow Past Year | -72,708,000 |
Free Cash Flow Prior Year | -37,985,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.02 |
MACD Signal | -0.06 |
20-Day Bollinger Lower Band | 1.63 |
20-Day Bollinger Middle Band | 2.82 |
20-Day Bollinger Upper Band | 4.01 |
Beta | 1.21 |
RSI | 58.31 |
50-Day SMA | 8.25 |
150-Day SMA | 6.35 |
200-Day SMA | 5.98 |
System |
|
Modified | 5/5/2025 8:01:11 PM EST |